• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

GSK’s $10.6B Nuvalent takeover fails to impress investors as shares fall: here’s why

by June 9, 2026
written by June 9, 2026

GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can help drive future growth and offset looming patent expirations in its HIV portfolio.

The acquisition, announced on Tuesday, will give the British pharmaceutical giant access to three experimental lung cancer treatments, including two candidates currently under review by the US Food and Drug Administration and expected to receive regulatory decisions later this year.

While the deal strengthens GSK’s long-term ambitions in oncology, investors appeared unconvinced by the scale and price of the transaction.

GSK shares fell around 3% in early trading, making the stock one of the weakest performers on the FTSE 100, while Nuvalent shares surged nearly 38% in premarket trading in the United States.

Premium offer for promising cancer assets

Under the terms of the agreement, GSK will launch a cash tender offer of $124 per share for Nasdaq-listed Nuvalent, representing a roughly 40% premium to the company’s closing price on Monday.

Although the headline value of the transaction is $10.6 billion, GSK said its net investment would be approximately $9.4 billion after accounting for cash held on Nuvalent’s balance sheet.

The acquisition provides GSK with access to two late-stage lung cancer drug candidates and a third earlier-stage asset, giving the company multiple opportunities in one of the pharmaceutical industry’s most lucrative treatment areas.

GSK expects the deal to contribute to revenue growth and strengthen core operating profit from next year.

The company also said the acquisition would help cushion the impact of patent expirations for dolutegravir, a key HIV treatment, between 2028 and 2030.

The transaction remains incremental to GSK’s broader target of generating more than £40 billion ($53.4 billion) in annual sales by 2031.

Oncology remains central to growth strategy

The acquisition marks another step in GSK’s effort to rebuild its oncology business after exiting the sector more than a decade ago.

In 2015, GSK completed a major asset swap with Swiss pharmaceutical company Novartis, selling its oncology division in exchange for Novartis’ vaccines business.

The companies also merged their consumer healthcare operations, with GSK later buying out Novartis’ stake for $13 billion.

Since then, GSK has steadily rebuilt its cancer portfolio through acquisitions and licensing agreements.

Previous deals have included purchases of oncology-focused companies such as Tesaro, Sierra Oncology, and IDRx.

Chief Executive Luke Miels described the company’s approach as a gradual rebuilding process.

“Our strategy has been a brick-by-brick building approach,” Miels told reporters.

Unlike many of GSK’s recent acquisitions, which focused on single-product companies, the Nuvalent deal brings multiple assets under one transaction.

Miels said the acquisition remains consistent with GSK’s strategy of targeting companies with validated science that address shortcomings in existing treatments.

Investors question size and timing

Despite the strategic rationale, analysts said the market reaction reflected concerns over the scale of the investment and the risks attached to Nuvalent’s pipeline.

Russ Mould, investment director at AJ Bell, said investors appear wary of the size of the acquisition and the premium GSK is paying.

“GSK is paying a hefty premium to get the deal over the line, and the two big lung cancer products flagged by Luke Miels still await regulatory approval,” Mould said.

“In rolling the dice on such a big transaction, he is undoubtedly taking a risk.”

Victoria Scholar, head of investment at Interactive Investor, echoed those concerns, noting that the deal is significantly larger than most of GSK’s previous acquisitions.

“GSK shares are down around 3% today, reflecting the fact that this is a mammoth deal even by GSK’s standards,” Scholar said.

She noted that the acquisition dwarfs previous oncology deals such as Tesaro and Sierra Oncology and carries execution risks given the reliance on regulatory approvals and future commercial success.

Growth potential outweighs near-term concerns

Despite investor caution, analysts acknowledged that GSK is securing a substantial oncology pipeline through a single transaction.

The company believes the acquisition will begin contributing to sales growth and earnings expansion from next year without disrupting its dividend policy.

Miels said GSK would need time to integrate Nuvalent but stressed that the company would retain the financial flexibility to pursue additional opportunities if attractive assets emerge.

The post GSK’s $10.6B Nuvalent takeover fails to impress investors as shares fall: here’s why appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Dow futures climb 125 points: 5 things to know before Wall Street opens
next post
Auburn student whose body was found after he went missing in Japan was on a ‘decompression’ hike

related articles

Anthropic’s ANT closes at $97.17, up 17% on...

November 19, 2026

Evening digest: Anthropic makes historic debut, AMD falls...

November 19, 2026

Nvidia stock falls for sixth day as Anthropic...

November 19, 2026

Aswath Damodaran values Anthropic at $76 a share,...

November 19, 2026

Anthropic pops 34% to cross $2 trillion valuation...

November 19, 2026

Anthropic CEO Dario Amodei defends $900B AI spending...

November 19, 2026

Temu owner just cut its marketing bill: stock...

November 19, 2026

Best Trading Platforms to Buy Anthropic Stock (ANT)

November 19, 2026

AMD stock falls 7% as Hunterbrook alleges links...

November 19, 2026

Anthropic IPO: How much could ANT stock rise...

November 19, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Nvidia, AMD and Intel stocks rebound sharply: is Wall Street’s AI panic easing?

    November 6, 2026
  • Apple shares fall 1.5% as iPhone 18 Pro launch comes with $100 price ike

    September 9, 2026
  • Nike outlines $5B growth plan as turnaround faces challenges in China and sportswear

    November 17, 2026
  • Analyst: owning SpaceX stock via this telecom name is an ‘attractive proposition’

    June 17, 2026
  • Top 3 catalysts for the S&P 500 Index this week: bonds, earnings season, CPI

    October 12, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026
  • 5

    Intel, AMD stocks slide again in aftermath of Broadcom’s weak outlook

    June 5, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,663)
  • Stock (90)

Latest Posts

  • Why is KOSPI surging after last week’s brutal market crash?

    November 10, 2026
  • Asian tech stocks rally as SK Hynix vows $75B in shareholder returns after Q3 beat

    October 28, 2026
  • Trump says US won’t slow AI as he calls AI ‘Super Intelligence’

    September 22, 2026

Recent Posts

  • What happens to SpaceX stock after lockup period ends?

    June 19, 2026
  • Anthropic’s IPO Valuation cut: is it bad news for AI bulls?

    October 18, 2026
  • How Elon Musk’s SpaceX triggered an $11 billion earnings shock for Alphabet

    October 29, 2026

Editor’s Pick

  • Micron stock plunges: Has it topped, or is this a rare buying opportunity?

    July 16, 2026
  • Paramount Skydance stock in Focus as odds of Warner Bros deal closing rise

    September 21, 2026
  • Rolls-Royce share price rebound has stalled: is it a buy as it reaffirms guidance?

    November 13, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock